GlassScriptPhysician profile
Baishali Nair
NPI 1972586600
$11,911.82
in general payments reported to CMS, 2019-2025
33 companies · $2,558 in 2025
The $2,558 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $547 · 2021: $1,672 · 2022: $1,621 · 2023: $2,189 · 2024: $2,737 · 2025: $2,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,471 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,470.55 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,811.88 | 2019-2025 | Lokelma, Farxiga |
| Fresenius USA Marketing, INC. | $1,197.95 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Vifor Pharma, INC. | $1,035.03 | 2019-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $958.27 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $834.57 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $698.85 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $578.39 | 2021-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $477.41 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $454.94 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $454.92 | 2020-2025 | Benlysta, Jesduvroq |
| Travere Therapeutics, INC. | $449.92 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $418.12 | 2019-2024 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $362.48 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $339.25 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Horizon Therapeutics Plc | $205.89 | 2021-2023 | Krystexxa |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $199.23 | 2020-2023 | Injectafer |
| Ani Pharmaceuticals, INC. | $180.83 | 2023-2025 | Purified Cortrophin Gel |
| Nxstage Medical, INC. | $173.31 | 2019-2025 | Liberty Select Cycler, Nxstage System One |
| Mallinckrodt Hospital Products INC. | $161.66 | 2022-2025 | Acthar, Terlivaz |
| Ardelyx, INC. | $152.48 | 2023-2025 | Ibsrela |
| Sanofi-Aventis U.S. LLC | $121.82 | 2024 | |
| Lilly USA, LLC | $114.99 | 2023-2025 | Jardiance |
| Akebia Therapeutics INC | $102.51 | 2019-2025 | Vafseo |
| Alexion Pharmaceuticals, INC. | $101.39 | 2019-2024 | Ultomiris |
| Kyowa Kirin, INC. | $91.86 | 2023-2025 | Crysvita |
| Takeda Pharmaceuticals U.S.A., INC. | $48.02 | 2024 | Gattex |
| Ultragenyx Pharmaceutical INC. | $38.34 | 2021 | |
| Chiesi USA, INC. | $35.43 | 2025 | Elfabrio |
| Amicus Therapeutics, INC. | $34.19 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.66 | 2025 | Jynarque |
| Pharmacosmos Therapeutics INC. | $24.03 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.72 | 2019 | |
| Cormedix INC. | $14.48 | 2024 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baishali Nair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.